Skye Bioscience grants director 75,000 stock options
Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share. The options were awarded at no upfront cost, expire on March 31, 2036, and vest in equal monthly installments over one year beginning March 31, 2026. This filing reflects a compensation-related equity award rather than an open-market purchase or sale of shares.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Schwab Andrew J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 75,000 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 75,000 contracts (Direct)
Footnotes (1)
- F1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Key Figures
Option grant size: 75,000 options
Exercise price: $0.615 per share
Underlying shares: 75,000 shares
+3 more
6 metrics
Option grant size
75,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$0.615 per share
Exercise price for underlying common stock
Underlying shares
75,000 shares
Common Stock underlying the option
Expiration date
March 31, 2036
Option expiration for the grant
Vesting start
March 31, 2026
Vests in equal monthly installments over one year
Post‑grant derivative holdings
75,000 options
Total options held after this transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "0.6150""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-03-31T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The stock option vests in equal monthly installments over the one year period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"underlying_security_title: "Common Stock""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Skye Bioscience (SKYE) disclose about Andrew J. Schwab in this Form 4?
Skye Bioscience disclosed that director Andrew J. Schwab received a stock option grant for 75,000 shares of common stock. The award is a compensation-related option, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.
How many Skye Bioscience (SKYE) options did Andrew J. Schwab receive?
Andrew J. Schwab received stock options covering 75,000 shares of Skye Bioscience common stock. These options were granted as a single award and represent his reported derivative holdings following the transaction in this Form 4 filing.
What is the exercise price of Andrew J. Schwab’s Skye Bioscience (SKYE) options?
The stock options granted to Andrew J. Schwab have an exercise price of $0.615 per share. This means he can choose to buy Skye Bioscience common shares at $0.615 if he exercises the options after they vest and before expiration.
When do Andrew J. Schwab’s Skye Bioscience (SKYE) options vest?
The options granted to Andrew J. Schwab vest in equal monthly installments over one year, beginning March 31, 2026. This creates a 12‑month vesting schedule, gradually making portions of the 75,000‑share option exercisable each month.
What is the expiration date of Andrew J. Schwab’s Skye Bioscience (SKYE) options?
Andrew J. Schwab’s stock options expire on March 31, 2036. He must exercise any vested portions of the 75,000‑share grant before that expiration date; otherwise, the right to purchase those shares at $0.615 per share will lapse.
Does this Skye Bioscience (SKYE) Form 4 show any stock being bought or sold on the market?
No, the Form 4 reports a grant of stock options to Andrew J. Schwab rather than a market trade. It reflects a compensation-related award, with no open-market buying or selling of Skye Bioscience common shares disclosed in this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
